Trials / Unknown
UnknownNCT06114160
Knowledge of Pregnant Women Concerning Pertussis, Vaccination Against Pertussis and Cocooning Strategy
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 500 (estimated)
- Sponsor
- Université de Reims Champagne-Ardenne · Academic / Other
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Accepted
Summary
In France, it has been recommended since 2022 that pregnant women be vaccinated against pertussis from 20 to 36 weeks' gestation. This vaccination schedule is inspired by the Anglo-Saxon model and studies showing the effectiveness of this practice. The aim of this vaccine is to protect the newborn by transferring antibodies from the fetus to the placenta, because Pertussis is a particularly serious disease in newborns.
Detailed description
The aim is to describe pregnant women's knowledge concerning pertussis, vaccination against pertussis during pregnancy and the cocooning strategy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Data collection | Data collection |
Timeline
- Start date
- 2023-12-01
- Primary completion
- 2024-02-01
- Completion
- 2024-05-01
- First posted
- 2023-11-02
- Last updated
- 2023-11-07
Source: ClinicalTrials.gov record NCT06114160. Inclusion in this directory is not an endorsement.